Last reviewed 2026-06-03 · How we verify

CD19-targetd CAR-T

Chongqing Precision Biotech Co., Ltd · Phase 1 active Biologic ✓ Verified Jun 2026 Quality 3/100

CD19-targetd CAR-T is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd. It is currently in Phase 1 development.

CD19-targeted CAR-T is a type of immunotherapy that targets the CD19 protein. It is being studied as a potential treatment for refractory Juvenile Dermatomyositis in a clinical trial (NCT06569472) conducted by Chongqing Precision Biotech Co., Ltd.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CD19-targetd CAR-T
Sponsor	Chongqing Precision Biotech Co., Ltd
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CD19-targetd CAR-T CI brief — competitive landscape report
CD19-targetd CAR-T updates RSS · CI watch RSS
Chongqing Precision Biotech Co., Ltd portfolio CI

Frequently asked questions about CD19-targetd CAR-T

What is CD19-targetd CAR-T?

CD19-targetd CAR-T is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd.

Who makes CD19-targetd CAR-T?

CD19-targetd CAR-T is developed by Chongqing Precision Biotech Co., Ltd (see full Chongqing Precision Biotech Co., Ltd pipeline at /company/chongqing-precision-biotech-co-ltd).

What development phase is CD19-targetd CAR-T in?

CD19-targetd CAR-T is in Phase 1.

Manufacturer: Chongqing Precision Biotech Co., Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing